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Over the past year, a series on commentaries have appeared in
the Toxicological Sciences Forum Series related to the 2007
National Research Council (NRC) publication, Toxicity Testing
in the 21st Century: A Vision and A Strategy. The first article in
the series provided an overview of the vision and was
accompanied by an editorial by the three editors of Toxicolog-
ical Sciences. During the past year, eight invited commentaries
from the academic, industrial, and regulatory sectors have
provided diverse perspectives on the vision, noted challenges to
its implementation, and highlighted aspects of toxicity testing
that were not addressed in the original NRC report. Here, we
offer a summary of the main points raised by the commentators
in tabular form, identify a number of common themes, and
finish the series by providing our perspective on several key
issues in charting the path forward to move from discussion to
action.
Key Words: toxicity pathway perturbations; in vitro-in vivo
extrapolations; 2007 NRC report on Toxicity Testing; adversity;
risk assessment of environmental agents.
Three years ago, the U.S. National Research Council
(NRC, 2007) published a report entitled Toxicity Testing
in the 21st Century: A Vision and a Strategy. The purpose
of this report was to develop a long-range strategic plan
to modernize the way environmental agents are tested for
toxicity. In a previous editorial in the Toxicological Sciences
Forum Series, Andersen and Krewski (2009) outlined the
components of the NRC vision; the editors subsequently
invited eight commentaries on this editorial (cf., Holsapple
et al., 2009). The present article provides a synthesis of
the various commentaries and some thoughts on moving
from discussion of the report to its implementation in
practice.
OVERVIEW OF COMMENTARIES
The eight commentaries covered a broad range of topics
(Table 1). Several overarching themes were present. Two of the
commentaries (Bus and Becker, 2009; Meek and Doull, 2009)
were extremely cautious, even pessimistic, about any rapid
change to the current toxicity testing methods without insuring
that the scientific tools were fit for purpose and that the results
could be appropriately applied beyond simply hazard identi-
fication. The pharmaceutical industry perspective (MacDonald
and Robertson, 2009) highlighted some differences in the
process of safety and risk assessment for environmental agents
and for pharmaceuticals. The pharmaceutical industry has had
more experience with mechanistic in vitro tests and high
throughput screening and brings valuable experience tempered
with some caution about setting overly high expectations for
the proposed toxicity testing technologies. These three were
categorized as ‘‘guarded to various degrees’’ in Table 1. Four
others, from Hartung (2009), Hubal (2009), Chapin and
Stedman (2009), and Boekelheide and Campion (2010), looked
primarily at issues relating to the process by which the NRC
vision could be implemented. Hartung (2009) focused on
regulatory change needed to facilitate any change in testing,
Chapin and Stedman (2009) outlined promises and challenges
with human stem cell technologies, and Hubal (2009) noted the
coordinate need for improved exposure assessment tools to
complement the toxicity testing initiative. Boekelheide and
Campion (2010) addressed the larger issue of how the results
from a battery of in vitro assays and associated interpretive
methodologies will be used to define ‘‘adversity.’’ These four
commentaries are ‘‘guardedly optimistic’’ in tone. The com-
mentary by Walker and Bucher (2009) provided a ‘‘one size is
not likely to fit all’’ warning about toxicity testing needs with
engineered nanomaterials. Table 1 highlights key points from
each commentary.
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TABLE 1
Summary of Commentaries on Toxicity Testing in the 21st Century: Bringing the Vision to Life
Commentary (authors) Specific comments
Original editorial
Toxicity testing in the 21st century:
bringing the vision to life
(Andersen and Krewski, 2009)
Current toxicity testing paradigm cannot meet the challenge of evaluating the large number (some
100,000) environmental agents to which humans are potentially exposed
NRC vision is based on understanding toxicity pathways and identification of critical pathway
perturbations that can lead to adverse health outcomes in humans
Critical pathway perturbations will be identified using suites of high throughput screen (HTS) assays
based on human cells and cell lines
A concerted effort on the part of the full scientific community will be required to bring the vision
to life
Introduction to the forum series
The vision for toxicity testing in the 21st century:
promises and conundrums (Holsapple et al., 2009)
Commitment to the three R’s: replacement, reduction, and refinement
Vision integrates state of the art mechanistic modeling and risk assessment approaches
Current toxicity testing practices originated 40–50 years ago and are time consuming and expensive
Boundaries of ‘‘adverse’’ and ‘‘adaptive’’ effects need to be clearly defined
Commentaries guarded to various degrees: Vision lacks specificity about how new toxicity testing results will be used
and how the new results will be interlaced with past experience
Pragmatic challenges for the vision of toxicity testing
in the 21st century in a regulatory context: another
Ames test?. . .or a new edition of ‘‘the Red Book’’?
(Meek and Doull, 2009)
Need to define what constitutes an adverse effect (cell homeostasis does not necessarily reflect an
adverse outcome)
NRC vision does not address short-term chemical risk management needs of regulatory agencies
Need to integrate pragmatic aspects of risk management to meet progressive regulatory requirements
Toxicity testing in the 21st century: a view from
the chemical industry (Bus and Becker, 2009)
Examine merits of tiered testing versus the use of a full battery of tests within the context of the NRC
vision
False positives and false negatives have different implications in the chemical and pharmaceutical
industries
NRC vision will test current default assumptions
HTS allows for a range of relevant dosages to be evaluated
Reservoir of current knowledge must be used
Must establish homeostatic tolerance limits of chemicals
Toxicity testing in the 21st century: a view from the
pharmaceutical industry (MacDonald and
Robertson, 2009)
In vitro and in vivo testing does not necessary predict adverse health outcomes
Proteomics and metabolomics will greatly enhance our understanding of how chemical interactions
can affect health risk
In silico chemical characterization will aid in the risk assessment process
Use a hybrid approach including both old and new testing strategies until the NRC vision is validated
Guardedly optimistic commentaries: The vision has clear merits, but what else is needed to ensure that a change of this magnitude will be successful?
A toxicology for the 21st century—mapping the
road ahead (Hartung, 2009)
Focus on test strategies instead of individual tests: Several tests combined will reduce
false positive rate
Consider specificity and sensitivity of the test when setting thresholds for what constitutes an
adverse effect
Although the gold standard for validation of new toxicity tests are in vivo test results, a mechanistic
standard would be more relevant
Evidence that the new toxicity testing methods are superior to existing methods will be needed to
motivate regulatory change
Globalization of markets may pose an obstacle to the implementation of the NRC vision:
International acceptance of the vision will be a prerequisite to its success
Quality assurance will be essential to the success of the vision: will need stringent quality standards
and documentation for the new types of toxicity tests
Need to organize the transition to the new type of testing through communication and workshops
Academia, industry, and government need to work together to implement the new vision
for toxicity testing
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COMMENTARIES ‘‘GUARDED TO VARIOUS DEGREES’’
Meek and Doull (2009) had the most pessimistic view of the
ability of the scientific community to bring the new
technologies described in the 2007 NRC report to bear in
toxicity testing. They argued that the committee should have
developed bridging strategies for moving from current practice
to the proposed new toxicity testing paradigm. In their view,
having such a plan in place early on would increase the
likelihood of long-term success and reduce the chance that the
proposal would alienate current practitioners. They also voiced
a concern that agents tested in these in vitro batteries will
produce multiple perturbations of pathways, as is now evident
from phase I ToxCast assay results (Judson et al., 2010).
Without a clearly defined approach to categorize in vitro effects
as beneficial, adverse, or irrelevant (normal variation), there is
the concern that pathway perturbation results will not be
credible as a risk assessment tool for the regulatory community.
They recommended taking a first step that would relate early
perturbations to apical endpoints in frameworks designed to
systematically consider key events in modes of action and their
subsequent implications for dose-response in risk assessment
(cf., Meek, 2008). This intermediate step in implementation of
any new testing process would be instrumental in advancing
common understanding in both the toxicological research and
the risk assessment communities in potential appropriate
application of data on early events in a toxicity pathway.
Increasing experience gained in making these comparisons
could then guide the transition from current practice to those
proposed in the 2007 report. Other clear concerns related to the
lack of consideration of other approaches, especially in Canada
and Europe, to developing progressive regulatory strategies to
address much larger numbers of chemicals within existing
testing and risk assessment programs. Such initiatives increase
throughput while maintaining the current primacy of animal
testing for establishing hazard. Summing up their comments
was the concern that the report might simply add a suite of
in vitro tests but lack the tools needed to interpret the results for
risk assessment purposes. This first commentary by Meek and
Doull (2009) presented a warning volley regarding the possible
downsides of moving toward what was seen as a vaguely
delineated mechanistic approach to human health risk assess-
ment, without a better definition of the transitional steps
necessary to bring the vision to life.
Bus and Becker (2009) offered several similar cautionary
notes from the perspective of the chemical industry. They
emphasized that in vitro methods are unlikely to capture the
broad range of intercellular and interorgan phenomena driving
expression of whole animal toxicity results and that transition
TABLE 1—Continued
Commentary (authors) Specific comments
Biologically relevant exposure science for the
21st century (Hubal, 2009)
New tools to measure environmental exposures need to be developed to define hazard-exposure
relationships within the context of the risk assessment process
Range of doses that are relevant to real-world exposures must be used in HTS in vitro assays
New NRC committee on exposure science in the 21st century will address outstanding issues in
exposure assessment
Endless possibilities: stem cells and the vision
for toxicity testing in the 21st century
(Chapin and Stedman, 2009)
HTS assays, one of the main elements of NRC vision, require robust, stable abundant cell lines
Stem cells may be advantageous because they can differentiate into any cell type and maintain their
genotype; there is an unlimited source of these cells
iPS stem cells derived from adult cells can be used to test sensitive phenotypes in the population
Stem cells can differentiate into 3D spheroids that may emulate in vivo models
Toxicity testing in the 21st century: using the
new toxicity testing paradigm to create
a taxonomy of adverse effects
(Boekelheide and Campion, 2010)
Regulatory health guidelines must clearly distinguish between adaptive and adverse responses
Presents a sequential model of adverse effects: A series of ‘‘latent failures’’ (such as electrophilicity
of the test chemical, irreversible toxicity pathway perturbations, abrupt dose-response transitions,
and mitochondrial dysfunction) can lead to ‘‘active failure’’ of an adverse effect
Development of a new paradigm to systematically analyze large reservoir of high throughput
screening data called the ‘‘Toxicological Factors Analysis and Classification System (TFACS)’’
Presents TFACS framework for defining adverse effects based on three tiered categories: chemical
characterization, toxicity pathways, and dose-response and extrapolation modeling
Information mined from databases and analyzed by TFACAS framework will establish a Taxonomy
of Adverse Effects
Taxonomy of Adverse Effects will require national and international collaboration
Commentary on challenges of novel environmental agents: The development of new chemistries will require attention to optimum test methods
and may not easily be transferred from in vivo technologies to in vitro HTS assays
A 21st century paradigm for evaluating the
health hazards of nanoscale materials?
(Walker and Bucher, 2009)
Nanoparticles possess unique characteristics with respect to dose, surface area, and behavior in
in vitro systems
Some, but not all, classes of nanoparticles could be tested in HTS assays
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to an in vitro testing system needs to be focused on identifying
true human health risks with a higher degree of confidence than
that associated with existing test systems. These new
technologies are likely to produce many false positives while
seeking to identify true human health risks through use of
human cells. On a positive note, it was stressed that new
technologies, such as those outlined in the NRC report, can
evaluate larger ranges of dose and associated modes of action.
In this manner, the tools may provide insights into refinements
of current default assumptions and risk models. In their closing
comments, they suggest that in order to effectively implement
the NRC vision, we must tap the knowledge base from our long
history of animal studies.
One point of clarification should be added. This commentary
(Bus and Becker, 2009) stated that the express intent of the
NRC vision was to replace live animal testing. Although
minimization of animal use was seen as desirable, the
committee was not focused on reduction in animal use as
a main criterion in its deliberations. The vision that emerged,
with limited animal use, was chosen because it represents the
preferred option for toxicity testing with improved in vitro test
methods, mode of action information using human cells as
pertinent testing systems, and understanding responses over
a range of concentrations.
The pharmaceutical perspective provided by MacDonald and
Robertson (2009) brings a different viewpoint from an industry
that has a primary focus on predicting and avoiding human
toxicity from compounds that will be administered to humans
at levels eliciting a beneficial response. This toxicity testing
constituency has concerns regarding interspecies extrapolation
but lesser concerns about extrapolations to low doses. The goal
with pharmaceuticals is to predict toxicity at levels where there
are biological effects in the majority of the patient population.
MacDonald and Robertson (2009) offered comments on the
inability of either in vitro or animal in vivo studies to be
completely predictive of subsequent human toxicity and that
a hybrid approach of in vivo test strategies with in vitro
mechanistic methods will likely be required until the new
vision in implemented. Overall, their comments show some
enthusiasm for the concepts underlying the NRC vision but
highlighted the need to inject a large dose of reality about
prospects to deliver on the promise of new and emerging
toxicity testing methodologies in the near term.
‘‘GUARDEDLY OPTIMISTIC’’ COMMENTARIES
Hartung (2009), bringing long experience in developing
alternative test strategies, noted that the vision appears to be an
idea whose time has come and focused primarily on challenges
in regulatory implementation once the technical aspects of the
vision are achieved. He listed 10 challenges. Some are very
practical. Challenge #3 (threshold setting) asks how the in vitro
results will produce a value for regulatory action. Challenge #4
(what to validate new test against) emphasizes mechanistic
validation, noting that continued validation against animal
studies will never overcome the inherent shortcomings of the
present testing strategies. (This challenge resonates well with
us. One of the most frequent questions we have been asked is
how the NRC vision will be validated. Validation cannot be
done against animal test results obtained at high doses that
we are seeking to replace; rather, validation can only be
achieved through an in-depth understanding of toxicity path-
ways, identification of critical pathway perturbations, and the
demonstration that in vitro tests are able to identify those
perturbations, with high sensitivity and specificity. Thus,
validation of the NRC vision will not be done against an
existing ‘‘gold standard,’’ but rather through a detailed
mechanistic understanding of toxicity pathways, as envisaged
by Hartung (2009).) Challenge #8 asks the broad question:
‘‘How to change with step by step developments becoming
now available?’’ Two basic strategies are mentioned: (1)
running two parallel approaches forward for comparison
purposes in preparation for the transition or (2) take new
problems and new opportunities and start the new paradigm
with these technologies or endpoints. He cautions that either
one has ‘‘the trap of just adding new patches without
substantial change,’’ concluding that we will have to approach
the transition in an organized fashion. Hartung’s (2009) paper
has a figure with the steps necessary to arrive at a new
approach to regulatory toxicology that deserves study by all of
us who are interested in bringing these new test methods to the
mainstream of regulatory risk assessment.
Chapin and Stedman (2009) discuss progress in stem cell
biology and the application of toxicity testing tools based on
stem cells for implementing the vision. They note two ways
that stem cells may be used in toxicity testing: (1) by
differentiation into cultures of ‘‘different’’ human cell types
whose response to chemicals can be tested and (2) by
evaluation of responses in their undifferentiated state (or
during differentiation). They discuss the development of 3D-
cultures (which they refer to as ‘‘tissue doppels’’) from multiple
cell types, including liver spheroids, and suggest how these
systems may be used in toxicity testing in the future. They
speculate:
‘‘On the other hand, it may be true that in the final version
of this testing scenario, we would not need to know how
a toxicity will manifest but would only need to know
which tissue doppels in vitro are sufficiently affected to
pass over the threshold of change into toxicity. Perhaps,
we will not need to reconstruct all the steps leading from
reduced neuronal steroid sensitivity to increased ovarian
steroid output to altered estrous cycle (persistent estrus) to
infertility; eventually, it may be that seeing the neuronal
change will be enough to flag a compound as potentially
toxic and lead to its testing in animals. It is likely that
in vitro testing would be designed to identify the
boundaries of threshold responses; the population health
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protection goal would then be to maintain corresponding
human exposures below these levels.’’
This high-level summary accurately captures the intended
directions for toxicity testing in the NRC report.
Boekelheide and Campion (2010) provided the final
perspective, discussing challenges of using in vitro rather than
in vivo test results for risk assessment. The collection of new
information will require a definition of apical endpoints to
change to a biological, chemical, or mechanistically based
endpoint based on in vitro systems. They propose a framework
for defining adverse effects based on three tiered categories:
chemical characterization, toxicity pathways, and dose-
response and extrapolation modeling with information mined
from databases and analyzed by a consistent framework to
establish a Taxonomy of Adverse Effects. In the discussion, the
paper provides an articulate overarching statement of a key
goal for Toxicity Testing in the 21st Century:
‘‘We all seek a mode of action–based molecular un-
derstanding of how the initiating events arising from the
interactions of a toxicant with a living system produce
adverse effects. One advantage of this new approach is
a deeper and coherent appreciation of the contributing
components that ultimately manifest as an adverse effect.’’
Hubal (2009) emphasized that successful implementation of
the NRC vision, including assay design and development of the
necessary tools for interpreting the results of the new assays for
purposes of human health risk assessment, is still only a step
along the way to achieving comprehensive risk assessments for
specific populations. A coordinated effort is also required to
modernize exposure science in order to measure environmental
exposures and insure that real-world exposures become a key
component of risk assessments based on in vitro test
methodologies. This recommendation reflects concerns of other
commentators that toxicity pathway perturbations need to be
interpreted both with respect to their relevance to a traditional
adverse health response and with respect to their relevance for
describing dose-response relationships for human populations.
COMMENTARY ON ‘‘CHALLENGES OF NOVEL
ENVIRONMENTAL AGENTS’’
Walker and Bucher (2009) warn that in vitro technologies
may not be useful for novel environmental agents, such as
nanomaterials, and that chemical characterization and the
interrelated aspects of dosimetry for nanomaterials would
require more attention than would be applied to most
chemicals. In addition, physical characteristics of these
materials may not be amenable to high throughput evaluations.
The NRC committee did foresee challenges with new
technologies that could require targeted in vivo testing and
novel protocol development before in vitro test systems could
be developed and validated. High throughput assays are more
likely to be useful for working with libraries of chemicals in
order to evaluate structural attributes of compounds activating
specific pathways. For any individual compound or small
numbers of compounds, the need is not high throughput but
assays that can be rapidly performed and interpreted to assess
perturbations (reflecting possible hazards) and possible risks
(i.e., determination of those hazards that are likely under
specific human exposure conditions). The goal of the NRC
report was to outline both toxicity testing and risk assessment
tools that would ensue from results of the assays, not simply
the endorsement of high throughput technologies.
RECURRING THEMES EXPRESSED IN THE
COMMENTARIES
We are grateful to the editors and the authors for the
thoughtful commentaries, even though some may have been
provocative on our first reading. Despite the broad diversity of
comments, there are a few general themes that deserve
attention. Before having these final thoughts, it is necessary
to recount the path from publication of the report in 2007 until
the present. There has been and remains significant interest in
the 2007 NRC report and its recommendations for modernizing
the manner in which we conduct toxicity tests with
environmental agents. Committee members have now provided
over 75 presentations on the NRC report since publication (see
Supplementary material for details). Our thoughts on the future
steps in moving the vision forward have been affected by our
service on the committee, by the efforts in report writing, by
the continuing dialog with both interested and skeptical
audiences, and by the contributions that are the focus of this
article. We acknowledge an enormous debt to all our fellow
committee members for their contributions to the formulation
of the original vision for the future of toxicity testing set out in
the 2007 NRC report. At the same time, it is difficult to
completely dissociate our postcommittee experiences over the
past 3 years in representing the toxicity testing report and
simply talk about the intent in the original NRC document.
With this caveat noted, we would like to discuss four recurring
themes. (1) Because not all responses observed in vitro assays
will be adverse, how will a determination be made as to which
responses warrant attention from a risk assessment perspective?
(2) Because in vivo responses frequently require multitissue
interactions absent from in vitro testing assays, how can apical
responses in intact mammalian systems be predicted on the
basis of in vitro data? (3) The ultimate goal of risk
characterization is the establishment of a recommended human
exposure guideline, traditionally done by extrapolation of
animal toxicity data to humans. Why the committee did not
propose methodologies for deriving human exposure guide-
lines based on toxicity pathway perturbations? And, (4) how
can such fundamental changes in the way we do toxicity testing
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be achieved in a smooth efficient manner? Are such changes
even possible?
Adversity
The 2007 NRC report discusses a continuum ranging from
subthreshold doses to moderate doses causing at most modest
responses with adaptation, through to higher doses with
perturbations that are likely to lead to adverse responses if they
were present in an in vivo situation. At present, such dose
dependencies are essentially ignored, with high dose-responses
treated as if they will occur throughout a wide dose range.
Thresholds are assumed for noncancer responses but subject to
application of multiple uncertainty factors, all treated as if they
are independent. The NRC report broadly outlined the role of
nonlinear computational systems biology modeling of response
pathway circuitry and network dynamics that underlie dose-
dependent transitions and that will likely guide discussions on
how we differentiate adaptive from adverse responses. These
computational models are under development for a limited
number of pathways, but the technology for toxicity pathway
mapping and dose-response modeling is developing rapidly in
the biomedical engineering arena. The contribution of the ‘‘dose-
response and extrapolation modeling’’ component of the NRC
vision, often overshadowed by the ‘‘toxicity testing’’ component,
will be key in making decisions about adversity, dose-dependent
transitions, and thresholds. The quantitative tools for these
assessments will need to develop along with the experimental
approaches for understanding pathway circuitry, pathway
dynamics, and defining adverse levels of perturbation. The
perspective by Boekelheide and Campion (2010) on adversity is
particularly pertinent to this point because one of the authors
(K.B.) was a member of the committee and takes a careful look
at questions of adversity through a postcommittee lens.
Predicting In Vivo Results from In Vitro Toxicity Pathway
Assay Results
This question—will the in vitro methods predict in vivo
responses—was not fully articulated in the original NRC
report. To address this point, it is important to remember that
the ultimate goal of toxicity testing is to prevent the occurrence
of adverse health effects in human populations exposed to
environmental agents. At present, this involves the identifica-
tion of (usually high) levels of exposure that will lead to
adverse health outcomes in animals, followed by extrapolation
to exposures that are not expected to lead to adverse health
effects in humans. The process expressed in the NRC report,
followed to its logical conclusion, will be to avoid critical
pathway perturbations: regulatory risk assessment will seek to
restrict human exposures to levels corresponding to those that
do not lead to excessive in vitro perturbations. Once an
appropriate suite of high throughput in vitro assays has been
developed, environmental agents capable of causing toxicity
pathway perturbations would be rapidly identified. In the
future, the emphasis in toxicological risk assessment would
shift toward the prediction of exposures that will not cause
critical toxicity pathway perturbations and away from the
present practice of identifying (high) levels of exposure in
animals that lead to adverse health effects as the point of
departure for establishing human exposure guidelines. (This
change in mindset is not appropriate for pharmaceuticals,
where the goal remains prediction of likely human responses to
biologically active levels of drugs.)
In many ways, this redirection of thinking about managing the
population health risks associated with environmental agents
may be the most difficult from a regulatory perspective. Today,
chemicals are labeled as toxic based on adverse health outcomes
seen at high doses in animals. Once labeled as ‘‘toxic,’’ it
becomes more difficult to remember that because of dose-
dependent transitions, compounds will usually pose little or no
risk to humans at ambient exposure levels. With the new
approach to toxicity testing, evaluation of the physical and
chemical properties of environmental agents, in silico evalua-
tions of structure activity relationships, and pathway activation
patterns identified in vitro might indicate that various end organ
responses could occur at sufficiently high exposures. Control
below some level consistent with the in vitro assay results and
extrapolation modeling would then predict regions of exposure
that would not demonstrate toxicity in humans. This change in
perspective—from risk assessment based on high dose animal
testing to risk avoidance based on results of in vitro assays—
would represent fundamental refocusing of the interpretation of
toxicity test results for inferring human health risks.
Setting Standards from Results of In Vitro Assays
With an in vitro concentration in hand that has caused an
‘‘excessive’’ perturbation, how would this be transformed into
a proposed acceptable tissue concentration and then to an
appropriate environmental exposure guideline for humans?
These are excellent questions, which the committee wisely
avoided. The use of uncertainty factors, especially the practice
of treating them as independent, and multiplying them together
is controversial. The manner in which these decisions will
evolve depends at least in part on the development of the
assays and the computational modeling of pathway dynamics.
This point was side stepped in the original NRC report and will
need to be revisited as the tools and technologies mature.
How Can the Change from Current Practices to a New
Paradigm Occur?
This point was raised forcefully by Meek and Doull (2009).
Our original perspective suggested taking the first steps by using
prototype compounds for which a comprehensive toxicological
database exists, including mode of action studies that indicate the
toxicity pathway(s) involved with higher dose toxicity. These
compounds could be tested in assays that query the known
targets of the environmental agent. These prototype assays
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would be test beds for the elucidation of toxicity pathways and
the development of computational systems biology models for
mechanistically motivated dose-response modeling, along with
physiologically-based pharmacokinetic modeling models for
in vitro to in vivo extrapolations. By taking advantage of
compounds with well-developed in vivo databases, comparisons
with the results of new test methods based on ‘‘21st century
approaches’’ would be facilitated. This process could be repeated
for several prototypes (Andersen, 2010) and the results and
proposed midcourse refinements used ‘‘to organize the transi-
tion,’’ as recommended by Hartung (2009).
SUMMARY
The NRC vision for the future of toxicity testing represents
a paradigm shift in the manner in which the toxic potential of
chemical substances will be assessed. The vision focuses on the
identification of critical perturbations of toxicity pathways that
may lead to adverse health outcomes in humans using modern
scientific tools and technologies. A particularly important
element of the vision is the use of suites of rapidly performed
in vitro assays using human cells that will be amenable to
scale-up for high throughput screening to process large
numbers of chemicals in a matter of days or weeks at a wide
range of doses, including those within the human exposure
range. The vision has received strong initial endorsement from
the scientific (Collins et al., 2008) and regulatory (Cohen et al.,
2008) communities, and aspects of the vision have been
incorporated into the recent U.S. Environmental Protection
Agency Strategic Plan for Evaluating the Toxicity of
Chemicals (EPA, 2009). The series of commentaries discussed
in the present article represent a healthy and necessary
discussion within the scientific community about the opportu-
nities and challenges provided by the NRC vision for the future
of toxicity testing.
The dialog within the scientific and regulatory communities
on the NRC vision is just beginning (Stokstad, 2009). The risk
assessment implications of the NRC vision were debated in
a parallel series of commentaries appearing in Risk Analysis in
2009 in response to an editorial by Krewski et al. (2009).
A forthcoming special issue of the Journal of Toxicology and
Environmental Health (2010) includes 14 invited papers that
discuss specific aspects of the NRC vision. These papers address
issues relating to computational toxicology, physiologically
based biokinetic and in silico modeling, exposure assessment,
current and future practices in toxicity testing, risk assessment,
and implementation of the NRC vision.
On one point, all the authors of the eight commentaries and
the two of us agree fully. This adventure will require collab-
orations across various groups in toxicology, in cell biology, and
in computational systems biology to bring this vision for the
future of toxicity testing to life. The path forward will not be
easy. It will require hard work, commitment to improving our
current test methods, and an ability to make midcourse changes
as scientific advances in toxicity testing are realized and the
interpretive tools needed to evaluate new toxicity test data
mature. The larger question is whether the effort is worthwhile.
Our opinion on this remains unchanged. Toxicity test methods
need to make better use of human biology and mode of action
information to adequately assess risks posed to humans at
relevant exposure levels. In addition, with the large number of
untested or inadequately tested environmental agents that lies
before us, the change proposed in the NRC vision for the future
of toxicity testing is desperately needed to provide public
confidence that compounds in commerce have been adequately
tested. We would like to conclude by expressing our sincere
thanks to all the authors of the commentaries for their thoughtful
reactions to the vision. We look forward to many more produc-
tive discussions on progress toward making the NRC vision a
reality in the years ahead.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci
.oxfordjournals.org/.
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